Podcasts about kenneth cusi

Part 2: Clinical Practice Guidelines for the Management of NAFLD: Understanding the Rationale for Screening 'High Risk' Patients: Managing NAFLD and NASH in People with T2 Diabetes: Disease Burden • Diagnosis • Current & Emerging Armamentarium with Kenneth Cusi, MD, FACP, FACE

This week, SurfingNASH.com is offering a 17-minute section of our new series, “The NASH Tsunami in Diabetes; Getting Ahead of the Rising Tide.” Rising Tide, as we call it, is a subscription-only series targeted at the primary care physicians, endocrinologists and allied health professionals who provide front-line treatments for patients living with Type 2 Diabetes and/or obesity.This conversation is an opportunity for NASH Tsunami listeners to learn about the series and why to subscribe by listening to this 17-minute segment of a previously unpublished episode from October, 2022, that is as timely today as when it was recorded.The full episode follows the experience of Fatty Liver Alliance Founder and President Michael Betel when he submitted to extensive non-invasive diagnostic testing to determine his own Fatty Liver status. Mike's experience, which he recorded for educational purposes and posted on Facebook, was a somewhat confusing experience due to inconsistencies in the results of various tests. In the episode, Rising Tide co-host Dr. Kenneth Cusi and episode guest (and NASH Tsunami co-host) Professor Jörn Schattenberg join Mike and co-host Roger Green to review Mike's test results and recommend courses of action for Mike to take. In this process, the group also discusses the Fatty Liver guidelines from AASLD, AACE, AGA and others and the pivotal role that front-line screening plays in these guidelines.This segment of the episode shares Mike's story and some of the feedback he received from Ken, Jörn and Roger. At the end of the episode, Roger provides guidance on how listeners can subscribe to the Rising Tide series.  

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Kenneth Cusi, MD, FACP, FACE From noninvasive tests to liver biopsies—what do we need to know about current diagnostic tools for nonalcoholic steatohepatitis (NASH)? Dr. Charles Turck joins Dr. Kenneth Cusi to dive into diagnostic guidelines and share the latest updates on these tools.

Host: John Buse, MD, PhD Guest: Kenneth Cusi, MD, FACP, FACE The American Association of Clinical Endocrinology (AACE) released new recommendations for the diagnosis and management of NAFLD and NASH. To learn more about these updates, Dr. John Buse speaks with Dr. Kenneth Cusi, who is the Chief of the Division of Endocrinology, Diabetes and Metabolism in the Department of Medicine at the University of Florida.

TRC Editor, Dr. Lori Dickerson, PharmD, FCCP talks with Kenneth Cusi, MD, FACP, FACE,  Professor of Medicine and Chief of the Division of Endocrinology, Diabetes and Metabolism from The University of Florida about managing nonalcoholic fatty liver disease.Listen in as they discuss considerations with managing nonalcoholic fatty liver disease (NAFLD)...including risk factors, screening, and treatment options.You'll also hear practical advice from panelists on TRC's Editorial Advisory Board:Anthony A. Donato, Jr., MD, MHPE, Associate Program Director, Internal Medicine from the Reading Health System, and Professor of Medicine at the Sidney Kimmel Medical College at Thomas Jefferson UniversityDouglas S. Paauw, MD, MACP, Professor of Medicine at the University of Washington School of MedicineCraig D. Williams, PharmD, FNLA, BCPS, Clinical Professor, Department of Pharmacy Practice at the Oregon Health and Science UniversityFor the purposes of disclosure, Dr. Cusi reports relevant financial relationships with Echosens, Inventiva, Nordic Pharma, Novo Nordisk, Poxel, Zydus (grants/research support); Ionis, Janssen, Genentech, Gilead, Madrigal, Merck, Novo Nordisk, Pfizer, Poxel, Terns Pharmaceuticals (consultant). The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.Pharmacist's Letter offers CE credit for this podcast. Log in to your Pharmacist's Letter account and look for the title of this podcast in the list of available CE courses.If you're not yet a Pharmacist's Letter subscriber, find out more about our product offerings at trchealthcare.com. Follow or subscribe, rate, and review this show in your favorite podcast app. You can also reach out to provide feedback or make suggestions by emailing us at ContactUs@trchealthcare.com. 

Nonalcoholic fatty liver disease (NAFLD) is a major public health problem that will only worsen in the future, as it is closely linked to the epidemics of obesity and type 2 diabetes mellitus. Given this link, endocrinologists and primary care physicians are in an ideal position to identify persons at risk to prevent the development of cirrhosis and comorbidities. Join endocrine expert Vin Tangpricha, M.D., Ph.D., as he interviews AACE Co-Chairs, guideline task force experts, Kenneth Cusi, MD, FACP, FACE, and Scott D. Isaacs, MD, FACP, FACE, about the newly released 2022 clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease, published in the May 2022 issue of Endocrine Practice (https://www.endocrinepractice.org/article/S1530-891X(22)00090-8/fulltext).

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Kenneth Cusi, MD, FACP, FACE Not only is nonalcoholic steatohepatitis (NASH) the most common chronic liver condition worldwide, but it's also becoming the number one cause of liver transplantation beyond hepatitis C. And with its growing prevalence and burden having no end in sight, Dr. Charles Turck speaks with Dr. Kenneth Cusi about how we can better recognize the symptoms of NASH in high-risk patient groups.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Kenneth Cusi, MD, FACP, FACE Not only is nonalcoholic steatohepatitis (NASH) the most common chronic liver condition worldwide, but it's also becoming the number one cause of liver transplantation beyond hepatitis C. And with its growing prevalence and burden having no end in sight, Dr. Charles Turck speaks with Dr. Kenneth Cusi about how we can better recognize the symptoms of NASH in high-risk patient groups.

NASH occurs in around 20% of individuals with NAFLD, and puts patients at high risk of poor outcomes including cardiovascular events and hepatocellular carcinoma. With people with type 2 diabetes and obesity at significantly increased risk for developing NAFLD, how can we identify those with NASH? In this podcast episode, we are joined by Dr Kenneth Cusi to discuss how patients can be risk stratified using non-invasive biomarkers and imaging techniques. By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at diabetes.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources. References: Nones RB et al. Can FIB4 and NAFLD fibrosis scores help endocrinologists refer patients with non-alcoholic fat liver disease to a hepatologist? Arch Endocrinol Metab. 2017 May-Jun;61(3):276-281. Shah AG et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009 Oct;7(10):1104-12. Newsome PN et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020 Apr;5(4):362-373. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. Obes Facts 2016;9(2):65-90. Disclosures: Dr Kenneth Cusi disclosures are as follows: Research Support - Poxel, Zydus, Echosens, Inventiva, Novo Nordisk Consultant - Allergan, Altimmune, Arrowhead, AstraZeneca, BMS, Boehringer Ingelheim, Coherus, Eli Lilly, Genentech, Gilead, Intercept, Janssen, Pfizer, Prosciento, Madrigal, and Novo Nordisk. Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity. Funding: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

Tune in to listen to Kenneth Cusi, MD talk about the increasing burden of NAFLD and NASH, important considerations for screening and diagnosis that clinicians in the community should be aware of, as well as perspectives about current and emerging treatments.

Lee Kaplan, MD, founding director of the Weight Center at Massachusetts General Hospital, discusses the relationship between NASH, obesity and associated comorbidities. This is episode 2 of our 6-part podcast, NASH: Take Action!, where leaders in gastroenterology, hepatology, endocrinology and primary care discuss the real-world, practical implications of screening, diagnosing and managing people with NAFLD and NASH. This series is hosted by Drs. Fasiha Kanwal, Kenneth Cusi and Jay H. Shubrook. To collect CME credit for listening, visit nash.gastro.org.

Robert H. Eckel, MD, University of Colorado, discusses limitations in current data about managing NAFLD and NASH and emerging therapies. This is episode 5 of our 6-part podcast, NASH: Take Action!, where leaders in gastroenterology, hepatology, endocrinology and primary care discuss the real-world, practical implications of screening, diagnosing and managing people with NAFLD and NASH. This series is hosted by Drs. Fasiha Kanwal, Kenneth Cusi and Jay H. Shubrook. To collect CME credit for listening, visit nash.gastro.org.

Vincent Wong, MD, The Chinese University of Hong Kong, provides insights into noninvasive diagnostic techniques for patients at high risk for NASH and the role of liver biopsy in diagnosing NASH. This is episode 4 of our 6-part podcast, NASH: Take Action!, where leaders in gastroenterology, hepatology, endocrinology and primary care discuss the real-world, practical implications of screening, diagnosing and managing people with NAFLD and NASH. This series is hosted by Drs. Fasiha Kanwal, Kenneth Cusi and Jay H. Shubrook. To collect CME credit for listening, visit nash.gastro.org.

Kim Pfotenhauer, DO, Michigan State University, and Eugene Wright, MD, Duke University, discuss screening people for NAFLD in the primary care setting. This is episode 3 of our 6-part podcast, NASH: Take Action!, where leaders in gastroenterology, hepatology, endocrinology and primary care discuss the real-world, practical implications of screening, diagnosing and managing people with NAFLD and NASH. This series is hosted by Drs. Fasiha Kanwal, Kenneth Cusi and Jay H. Shubrook. To collect CME credit for listening, visit nash.gastro.org.

We close out this series chatting with Hashem El-Serag, MD, Baylor College of Medicine, about collaboration between primary care providers and specialists in managing patients with NAFLD and NASH. This is the final episode in our 6-part podcast, NASH: Take Action!, where leaders in gastroenterology, hepatology, endocrinology and primary care discuss the real-world, practical implications of screening, diagnosing and managing people with NAFLD and NASH. This series is hosted by Drs. Fasiha Kanwal, Kenneth Cusi and Jay H. Shubrook. To collect CME credit for listening, visit nash.gastro.org.

This is episode 1 of our 6-part podcast, NASH: Take Action!, where leaders in gastroenterology, hepatology, endocrinology and primary care talk about the real-world, practical implications of screening, diagnosing and managing people with NAFLD and NASH. This series is hosted by Drs. Fasiha Kanwal, Kenneth Cusi and Jay H. Shubrook. We start with a discussion on the prevalence of NAFLD and NASH and their clinical and economic burdens with guest Zobair Younossi, MD, president, medicine service line, Inova Health System. To collect CME credit for listening, visit nash.gastro.org.

The last half of December marks our annual NAFLD Year-in-Review. Episodes 62-64 each include ~20 minute segments of longer interviews with Stakeholders who have made a dent in Fatty Liver disease in 2021. In this episode, Louise Campbell and Roger Green are joined by Manal Abdelmalek, Kenneth Cusi and Jörn Schattenberg.Highlights:3:26 – Manal Abdelmalek introduction and discussion: opportunities in the new drug pipeline and ways to treat using older agents until new agent arrive5:06 – Manal: urgent to treat cirrhosis when it appears. Reversal may not be “achievable;”  but blunting progression can provide stability  9:51 – We learn more about heterogeneity of cirrhosis patients all the time. Some day, genetics will pinpoint each patient's outcome to avoid so we can treat accordingly12:20 – Louise: would a combined database of multiple cirrhosis drug study patients provide richer insights?14:05 – Manal: let's “shelf,” not "trash," drugs that had promising NIT results but missed in Phase 2b or 3 histology 18:57 – Louise: Manal does well to remind us how to use older drugs to stabilize cirrhosis patients. 21:05 – Manal: until new drugs become commercially available in 2-5 years, using older drugs better will be key 23:07 – Ken Cusi introduction and discussion: development of multi-disciplinary activities and clinical care pathways24:10 – Ken: New data on prevalence and etiology of NASH cirrhosis spurred multi-specialty activities 24:41 – Key insight drivers: NHANES analyses, endorsements from medical societies and global journals, work of Jeff Lazarus and Wilton Park27:01 – 2022 a “great year:"  new/updated guidelines, major Phase 3 trials progressing 30:00 – Louise:  AGA critical care pathway work and collaboration among specialties pivotal, positive and extending to related consumer industries 31:26 – Ken: 2-3 years from now, foresees “convergence of awareness” to expand FIB-4 and other simple tests to more patient risk subgroups. 33:25 – Study in progress: screening large number of patients to determine NASH prevalence among non-diabetic patients 35:34 – There was significant debate whether to include screening for T2D patients in  the 2018 AASLD guideline recommendations37:03 – Louise: Fatty Liver disease has far broader implications than simply for the liver38:41 – Roger: asks how liver testing and vigilance will fit in  schedules and practices of already overburdened providers 39:55 – Ken:  requires a of simple, inexpensive, easily accessible  Stage 1 tests like FIB-4, was key to its selection42:22 – Jörn Schattenberg introduction and question: how are cost effectiveness analyses progression44:25 – Jörn: 2021 has been “an exceptional year” for NASH 46:04 – Collaborated with Vlad Ratziu and others to produce cost of illness study published in Liver International in 2021 49:39 -Louise:  why does it feel like we study cost effectiveness only for expensive new drugs and never measure cost effectiveness of inaction?50:38 – Jörn: value of monitoring relies on measuring related risks from cardiovascular and other systems52:22 – Roger:  re Louise's question, most cost effectiveness work evaluates a specific new expenditure, not a global “what if”55:44 – Jörn: quality-of-life, which has clear economic costs, strongly associated with NAFLD 57:14 – Roger: Using HER to identify patients at risk might be a more palatable way to target education and information 59:50 – Jörn: An Optum database algorithm built by NIDDK provides a look at how to target1:01:09 – Episode ends

Lead author Jeffrey Lazarus and co-author Jörn Schattenberg join Stephen Harrison, Louise Campbell, and Roger Green to discuss the groundbreaking paper "Advancing the Global Health Agenda for NAFLD." This conversation starts with Roger discussing the recent Episode 49, in which Kenneth Cusi presented the multi-specialty clinical care pathway approach fostered by the American Gastroenterological Association in harmony with other specialties and Scott Friedman's comments in Episode 55 about NASH as an environmental disease caused by changes in global diets and their effect on the liver through the microbiome. Jeff notes that he sees working in parallel with environmental and active lifestyle advocates as a cause for hope. The conversation shifts to the growth rates for cirrhosis in countries around the world and what that implies in terms of how fast the patient load will double or triple. This will cause increases in cost and worker demand nations are not prepared to address. The final question asks the group where panelists believe they can have the greatest impact, which leads to a follow-up question from Roger about whether stating aggressive incidence numbers might scare off payers, particularly private payers in the US. Jeff agrees this might be a risk as the session ends.

Last author and leading endocrinology Fatty Liver Opinion Leader Ken Cusi joins co-author Stephen Harrison, Louise Campbell and Roger Green to discuss the recent Clinical Care Pathway published in Gastroenterology.Last week, Gastroentrology published the article "Clinical Care Pathway for the Risk Stratification and Management of Patients with Nonalcoholic Fatty Liver Disease.This paper and its predecessor, "Preparing for the NASH Epidemic: A Call to Action," was the result of collaboration between leaders in endocrinology, diabetes care, bariatric medicine and obesity care, primary care, gastroenterologists and hepatologists. This paper presents a clear, straightforward multidisciplinary pathway for the identification, screening, diagnosis, risk stratification and management of NAFLD and NASH patients. It is truly a groundbreaking piece of work.Dr. Kenneth Cusi, who served as last author on both papers, joins the Surfers to discuss the effort that went into development of the pathway and critical elements for its adoption and use.Highlights include:7:40 - Ken Cusi begins to discuss his history with Stephen Harrison and work on the Clinical Care Pathways paper10:41 - Louise Campbell's initial reaction: "A pivotal piece"12:29 - Stephen Harrison discusses the way the group worked together13:54 - Ken's first goal: "to build the muscle" for non-hepatologists to think about Fatty Liver whenever treating a patient in the three targeted groups17:26 - Stephen identifies a key discussion point in the group: identifying at-risk patients to target18:48 - Why the group chose FIB-4 as its initial standard test20:57 - Ken's hope: medical societies asking their clinician members to screen the three groups regularly for Fatty Liver22:42 - Three items that struck Roger Green immediately22:35 - Ken's "down to earth" study of asymptomatic patients25:38 - Increasing awareness might drive two changes in prescribing behavior: doctors might select diabetes drugs with the liver in mind and not stop the patient's statins26:46 - Stephen reviews the 2021 San Antonio prevalence study29:54 - Stephen: What's changed since the 2011 San Antonio prevalence study? Moderate-to-severe NASH more than doubled!32:00 - Louise: liver disease should become part of the WHO initiative on diabetes33:07 - Ken explains elastography in simple terms35:10 - Stephen discusses principles of screening for NASH patients with significant cirrhosis risk36:07 - Stephen lists blood-based and imaging confirmatory options for clinicians who cannot access FibroScan or other in-office elastography38:11 - Roger: How does this translate into the last 5 or 10 patients a clinician saw?39:20 - Ken expresses optimism that new obesity drugs will motivate non-hepatologists to look for NASH harder and treat it more aggressively40:41 - Louise raises two more questions42:14 - Stephen's closing comments: we're at the beginning, like the Wright Brothers43:32 - Louise's closing comments: education, education, education...and advocacy44:22 - Ken's closing comments: share hepatologists' knowledge with other specialties to improve screening and care of Fatty Liver disease46:04 - Roger's closing comment: if a journey of 1,000 miles starts with a single step, this is like starting with a marathon47:17 - Business report -- CME credits for Surfing the NASH Tsunami, the reason for two sponsors and an exciting schedule ahead

A comprehensive review article in the April issue of Gastroenterology looks at the role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis. Dr. Kuemmerle speaks to author Dr. Kenneth Cusi.